Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
NCT06257706

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Led by Alimentiv Inc. · Updated on 2026-01-15

304

Participants Needed

69

Research Sites

234 weeks

Total Duration

On this page

Sponsors

A

Alimentiv Inc.

Lead Sponsor

T

Takeda

Collaborating Sponsor

AI-Summary

What this Trial Is About

Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical symptoms + biomarkers is superior to a target of clinical symptoms + biomarkers alone in achieving CS-free endoscopic remission measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD). Qualified participants will be randomly assigned in a 1:1 ratio to one of 2 different target treatment groups. Group 1: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. At Week 22 and 30, the IUS-based component of the target will be IUS response and at Week 38, the final treatment target will be TMH. Group 2: Participants will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission.

CONDITIONS

Official Title

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 80 years
  • Moderately to severely active Crohn's disease with CDAI score 220 to 450 and SES-CD scores excluding severe narrowing
  • Bowel wall thickness over 4.0 mm on intestinal ultrasound in the terminal ileum or colon (except rectum)
  • Biologic-naive or previous exposure to no more than one advanced therapeutic for Crohn's disease within last 5 years
  • Stable dose of 5-ASA for Crohn's disease started at least 4 weeks before screening
  • Negative pregnancy test and use of effective contraception for persons who can bear children; documentation if unable to bear children
  • Able to fully participate in all study procedures
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Previous or current treatment with vedolizumab, etrolizumab, or natalizumab
  • Exposure to two or more advanced therapeutic compounds for Crohn's disease
  • Recent changes to oral corticosteroid dose within 2 weeks before randomization or corticosteroid dose over 40 mg prednisone equivalent
  • Inflammation only proximal to terminal ileum not reachable by ileocolonoscopy
  • Complications such as symptomatic strictures with significant prestenotic dilation requiring intervention
  • Extensive colonic resection or missing more than two colon segments, ileorectal anastomosis, or proctocolectomy
  • Presence of ostomy or ileoanal pouch
  • Short bowel syndrome
  • Fibrotic-only strictures without active inflammation including impassable stenosis
  • Abscess larger than 2 cm detected by ultrasound or endoscopy
  • Serious diseases or infections that may affect participation or safety
  • Positive Clostridioides difficile stool test
  • Known HIV, hepatitis B or C infection without recent negative tests
  • Active or latent tuberculosis without recent negative tests
  • Other significant systemic or recurring infections within 6 months
  • History or signs of progressive multifocal leukoencephalopathy
  • Allergy or intolerance to vedolizumab or its components
  • Active severe infections such as sepsis or opportunistic infections
  • Unwillingness to avoid prohibited medications during the trial
  • Participation in another clinical trial or investigational therapy within 30 days
  • History of alcohol or drug abuse affecting compliance
  • Previous enrollment in this study
  • Pregnancy, lactation, or intention to become pregnant/impregnate during or shortly after the study
  • Live or live-attenuated vaccination within 4 weeks prior or planned during the study
  • Mandatory military service, deprivation of liberty, or judicial limitations
  • Immediate family or dependent relationship with study staff involved in this trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 69 locations

1

TLC Clinical Research Inc - Los Angeles

Los Angeles, California, United States, 90048

Withdrawn

2

Medical University of South Carolina (MUSC)

Charleston, South Carolina, United States, 29425

Not Yet Recruiting

3

Houston Methodist Hospital

Houston, Texas, United States, 77030

Actively Recruiting

4

Concord Repatriation General Hospital

Concord, New South Wales, Australia, 2139

Actively Recruiting

5

Mater Misericordiae Ltd

South Brisbane, Queensland, Australia, 4101

Actively Recruiting

6

Calvary Adelaide Hospital

Adelaide, South Australia, Australia, 5000

Actively Recruiting

7

Royal Adelaide Hospital

Adelaide, South Australia, Australia, 5000

Actively Recruiting

8

The Queen Elizabeth Hospital

Woodville, South Australia, Australia, 5011

Actively Recruiting

9

Northern Hospital Epping

Epping, Victoria, Australia, 3076

Actively Recruiting

10

Austin Health

Heidelberg, Victoria, Australia, 3084

Actively Recruiting

11

The Alfred Hospital

Melbourne, Victoria, Australia, 3004

Actively Recruiting

12

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Actively Recruiting

13

Harry Perkins institute of Medical Research - Fiona Stanley Hospital

Murdoch, Western Australia, Australia, 6150

Actively Recruiting

14

VITAZ - AZ Nikolaas

Sint-Niklaas, Antwerpen, Belgium, 9100

Actively Recruiting

15

Imelda Ziekenhuis Bonheiden

Bonheiden, Antwerp, Belgium, 2820

Actively Recruiting

16

University Hospital Ghent

Ghent, East Flanders, Belgium, 9000

Actively Recruiting

17

UZ Leuven-University Hospital Gasthuisberg

Leuven, Flemish Brabant, Belgium, 3000

Actively Recruiting

18

AZ Delta - Rumbeke Campus

Roeselare, West Flanders, Belgium, 8800

Actively Recruiting

19

ULB Hopital Erasme

Brussels, Belgium, 1070

Actively Recruiting

20

University of Calgary

Calgary, Alberta, Canada, T2N 4Z6

Actively Recruiting

21

University of Alberta, Dept of Medicine, Division of Gastroenterology

Edmonton, Alberta, Canada, T6G 2X8

Actively Recruiting

22

Viable Clinical Research - Bridgewater

Bridgewater, Nova Scotia, Canada, B4V 3N2

Actively Recruiting

23

LHSC - University Campus

London, Ontario, Canada, N6A 5A5

Actively Recruiting

24

LHSC - Victoria Hospital

London, Ontario, Canada, N6A 5W9

Not Yet Recruiting

25

Toronto Immune and Digestive Health Institute Inc. (TIDHI)

Toronto, Ontario, Canada

Actively Recruiting

26

Vojenska nemocnice Brno

Brno, South Moravian, Czechia, 615 00

Not Yet Recruiting

27

Fakultni Nemocnice Brno

Brno, South Moravian, Czechia, 625 00

Not Yet Recruiting

28

Herlev Hospital

Herlev, Capital Region, Denmark, 2730

Actively Recruiting

29

Nordsjaellands Hospital - Hillerod

Hillerød, Capital Region, Denmark, 3400

Actively Recruiting

30

Bispebjerg Hospital

Copenhagen NV, Capital, Denmark, 2400

Actively Recruiting

31

Hvidovre Hospital

Hvidovre, Capital, Denmark, 2650

Actively Recruiting

32

Aarhus Universitetshospital

Aarhus, Central Denmark, Denmark, 8200

Actively Recruiting

33

Randers Regional Hospital

Randers, Central Denmark, Denmark, 83930

Actively Recruiting

34

Sjaellands Universitets hospitall Koge

Køge, Region Sjælland, Denmark, 4600

Withdrawn

35

Svendborg Hospital

Svendborg, Denmark

Withdrawn

36

Hopital Lyon Sud

Pierre-Bénite, Auvergne-Rhône-Alpes, France, 69495

Actively Recruiting

37

APHM

Marseille, Provence-Alpes-Côte d'Azur Region, France, 13015

Actively Recruiting

38

Groupe Hospitalier Prive Ambroise Pare - Hartmann

Neuilly-sur-Seine, France

Withdrawn

39

Universitatsklinikum Augsburg

Augsburg, Bavaria, Germany, 86156

Not Yet Recruiting

40

Universitatsklinkum Frankfurt - Goethe Universitat

Frankfurt am Main, Hesse, Germany, 60590

Withdrawn

41

Klinikum Luneburg

Lüneburg, Lower Saxony, Germany, 21339

Actively Recruiting

42

Universitaetsklinikum Schleswig-Holstein (UKSH)- Campus Kiel

Kiel, Schleswig-Holstein, Germany, 24105

Actively Recruiting

43

Universitats Klinikum Freiburg

Freiburg im Breisgau, Germany

Withdrawn

44

Ospedale Casa Sollievo della Sofferenza IRCCS

San Giovanni Rotondo, Foggia, Italy, 71013

Actively Recruiting

45

Ospedale Luigi Sacco

Milan, Lombardy, Italy, 20157

Actively Recruiting

46

Ospedale San Raffaele S.r.I.

Milan, Milan, Italy, 20132

Not Yet Recruiting

47

Policlinico Universitario Agostino Gemelli

Roma, Rome, Italy, 00168

Actively Recruiting

48

Radboud University Nijmegen Medical Centre

Nijmegen, Gelderland, Netherlands, 6525

Actively Recruiting

49

Amsterdam UMC - VU Medisch Centrum

Amsterdam, North Holland, Netherlands, 1081HV

Actively Recruiting

50

Erasmus Medisch Centrum (MC)

Rotterdam, South Holland, Netherlands, 3015 GD

Not Yet Recruiting

51

ETZ - St. Elisabeth Hospital

Tilburg, Netherlands

Withdrawn

52

Oddzial Gastroenterologiczny SP ZOZ w Lecznej

Łęczna, Gmina Leczna, Poland, 21-010

Actively Recruiting

53

SOLUMED Centrum Medyczne

Poznan, Greater Poland Voivodeship, Poland, 60-529

Actively Recruiting

54

GASTROMED - Kopon, Zmudzinski I Wspolnicy Sp.j.

Torun, Kuyavian-Pomeranian Voivodeship, Poland, 87-100

Actively Recruiting

55

Melita Medical Sp Zoo

Wroclaw, Lower Silesian Voivodeship, Poland, 53-611

Actively Recruiting

56

Bodyclinic Sp.z.o.o. Sp.K

Warsaw, Masovia, Poland, 03-712

Actively Recruiting

57

WIP Warsaw IBD Point Profesor Kierkus

Warsaw, Masovia, Poland, 04-501

Actively Recruiting

58

Centrum Medyczne Medyk

Rzeszów, Podkarpackie Voivodeship, Poland, 35-326

Actively Recruiting

59

Vita Longa Sp. z o.o.

Katowice, Silesian, Poland, 40-748

Actively Recruiting

60

Sonomed Sp. z o.o. - Centrum Medyczne

Szczecin, West Pomerianian, Poland, 71-685

Actively Recruiting

61

Twoja Przychodnia-Centrum Medyczne Opole

Opole, Poland

Withdrawn

62

EuroMediCare (EMC) Instytut Medyczny SA

Wroclaw, Poland, 54-144

Actively Recruiting

63

LisbonCentro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria

Lisbon, Portugal

Not Yet Recruiting

64

Nottingham University Hospitals NHS Trust - QMC

Nottingham, East Midlands, United Kingdom, NG7 2UH

Actively Recruiting

65

London North West University Healthcare NHS Trust - Northwick Park Hospital

Harrow, Middlesex, United Kingdom, HA1 3UJ

Withdrawn

66

Western General Hospital

Edinburgh, United Kingdom, EH4 2XU

Not Yet Recruiting

67

Barts Health NHS Trust - The Royal London Hospital

London, United Kingdom, E1 2AJ

Actively Recruiting

68

University College London Hospitals NHS Foundation Trust

London, United Kingdom, NW1 2BU

Actively Recruiting

69

Kings College Hospital NHS Foundation Trust

London, United Kingdom, SE5 9RS

Actively Recruiting

Loading map...

Research Team

E

Elena van Hest

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here